Tobira Therapeutics Inc
Most Recent
Allergan Enters the Attractive NASH Market
Although hepatitis C is the most common cause resulting in liver transplants today, NASH (nonalcoholic steatohepatitis) will replace it by 2030.
Understanding Gilead Sciences’ NASH Pipeline
Simtuzumab is Gilead Sciences’ (GILD) most advanced NASH (nonalcoholic steatohepatitis) anti-fibrotic product.